To provide for a limitation on availability of funds for Related Agencies, John F. Kennedy Center for the Performing Arts, Capital Repair and Restoration for fiscal year 2024.

Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Drug Act (H.R. 2214) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (118th Congress) Pharmacy Benefit Manager Transparency Act of 2025 (S. 526) Pharmacy Benefit Manager Reform Act (118th Congress) Patients Before Middlemen Act (S.882) Prescription Drug Transparency and Affordability Act (H.R. 2450) Pharmacists Fight Back Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) One Big Beautiful Bill Act (H.R. 1) Consolidated Appropriations Act of 2026 (H.R.7148)

Client expense: $2,070,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues SECURE Rx Act of 2026 (draft) User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 882: Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 2710: Open Payments Expansion Act S. 3345: PBM Price Transparency and Accountability Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act H.R. 3701 Family Vaccine Protection Act H.R. 4132: Prescription Information Modernization Act of 2025 H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6283 Delinking Revenue from Unfair Gouging (DRUG Act) Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Drug Act (H.R. 2214) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (118th Congress) Pharmacy Benefit Manager Transparency Act of 2025 (S. 526) Pharmacy Benefit Manager Reform Act (118th Congress) Patients Before Middlemen Act (S.882) Prescription Drug Transparency and Affordability Act (H.R. 2450) Pharmacists Fight Back Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) Full-Year Continuing Appropriations and Extensions Act of 2025 (H.R.1968) One Big Beautiful Bill Act (H.R. 1)

Client expense: $1,530,000 · Firm income: Not reported

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 2710: Open Payments Expansion Act S. 3345: PBM Price Transparency and Accountability Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation S. 2305/H.R. 5526 The Biosimilar Red Tape Elimination Act-- To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Education on real time benefits checks for prescriptions

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Drug Act (H.R. 2214) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (118th Congress) Pharmacy Benefit Manager Transparency Act of 2025 (S. 526) Pharmacy Benefit Manager Reform Act (118th Congress) Patients Before Middlemen Act (S.882) Prescription Drug Transparency and Affordability Act (H.R. 2450) Pharmacists Fight Back Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) Full-Year Continuing Appropriations and Extensions Act of 2025 (H.R.1968) One Big Beautiful Bill Act (H.R. 1)

Client expense: $2,040,000 · Firm income: Not reported

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Acccess to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Give Kids a Chance Act of 2025 H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 2821: FDA Modernization Act 3.0 H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements

S. 891, The Bipartisan Health Care Act, provisions related to PBM regulation H.R. 10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers H.R. 2214, The DRUG Act -provisions related to PBM compensation H.R. 5378 (118th Congress), Lower Cost, More Transparency Act S. 526 Pharmacy Benefit Manger Transparency Act of 2025 -provisions related to transparency and pharmacy and PBM compensation S, 1339 PBM Reform Act (118th Congress) provisions related to PBM compensation Draft legislation, Patients Before Middlemen regarding payor ownership of pharmacies General education on ERISA and PBMs

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.526 - Pharmacy Benefit Manager Transparency Act of 2025; S. 1339 - Pharmacy Benefit Reform Act (118th Congress); S. 1542/H.R. 2214 - DRUG Act (118th Congress); S. 1038/H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 (118th Congress); S. 5503/H.R. 10362 - PBM Act of 2024 (118th Congress).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Protecting Patients Against PBM Abuses Act (118th Congress) Drug Act (H.R. 2214) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (118th Congress) Pharmacy Benefit Manager Transparency Act of 2025 (S. 526) Pharmacy Benefit Manager Reform Act (118th Congress) Patients Before Middlemen Act (S.882) Prescription Drug Transparency and Affordability Act (H.R. 2450) Pharmacists Fight Back Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) Full-Year Continuing Appropriations and Extensions Act of 2025 (H.R.1968) One Big Beautiful Bill Act (H.R. 1)

Client expense: $1,380,000 · Firm income: Not reported

H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.526 - Pharmacy Benefit Manager Transparency Act of 2025; S. 1339 - Pharmacy Benefit Reform Act (118th Congress); S. 1542/H.R. 2214 - DRUG Act (118th Congress); S. 1038/H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 (118th Congress); S. 5503/H.R. 10362 - PBM Act of 2024 (118th Congress).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug Patent Reform Pharmacy Benefit Manager (PBM) operations and practices, Spread Pricing, Rebates, Delinking Protecting Patients Against PBM Abuses Act (118th Congress) Drug Act (H.R. 2214) Robinson-Patman Act Reform Modernizing and Ensuring PBM Accountability (MEPA) Act (118th Congress) Pharmacy Benefit Manager Transparency Act of 2025 (S. 526) Pharmacy Benefit Manager Reform Act (118th Congress) Patients Before Middlemen Act (S.882) Prescription Drug Transparency and Affordability Act (H.R. 2450) Pharmacists Fight Back Act (118th Congress) Lower Cost, More Transparency Act (118th Congress) Full-Year Continuing Appropriations and Extensions Act of 2025 (H.R.1968)

Client expense: $2,520,000 · Firm income: Not reported

H.R.2214 The DRUG Act - provisions related to PBM compensation. H.R.10445 (118th Congress), Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress), Lower Cost, More Transparency Act. Advanced Premium Tax Credits continuation. S.526 Pharmacy Benefit Manger Transparency Act of 2025. S.891, The Bipartisan Health Care Act, provisions related to PBM regulation.

Client expense: $420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE